Smart scales and special clinics to help thousands of obese children lose weight
Thousands of severely overweight children could be helped by hi-tech 'smart scales' as part of an NHS England campaign to support weight loss and promote healthy habits.
The digital device, hailed by health chiefs as a 'game-changing tool,' is being rolled out at specialist NHS clinics where staff can monitor and provide ongoing weight loss help to patients and their families.
About 350 patients are already using the smart scales, which have 'hidden digits' that connect to a mobile app.
It visually shows the 'direction of their weight management' without displaying specific numbers, a spokesman said.
The data is automatically transferred to the patient's clinical team, who can keep in touch with the family through the app to send regular personalised feedback.
This would be done in line with any behavioural changes that may be needed.
The aim is to deliver expert care at home and cut down on the need for frequent hospital visits, for a range of potential issues such as stroke and mental health problems.
The pilot scheme is being rolled out at 15 Complications from Excess Weight (CEW) clinics.
So far 4,784 children and young people, aged from two to 18, living with severe obesity in England, have received care for complications or conditions linked to excess weight from 32 specialist NHS clinics, since 2021.
Another 150 children are in line to use the new smart scales tool and app when it is rolled out to four more clinics this summer, according to NHS England.
Professor Simon Kenny, NHS England's national clinical director for children and young people, said: 'This game-changing tool is helping our specialists support and keep track of children's weight-loss progress without them needing to leave home, while offering regular advice to them and their parents to help build healthy habits.
'Living with excess weight can cause problems affecting every organ system and long-term complications such as type 2 diabetes, stroke, early joint replacements and mental health difficulties.
'We also know that children living with health problems have poorer school attendance, which can affect their future employment and life opportunities – and the NHS won't just sit by and let children and young people become ill adults.'
Early intervention can help limit excess weight gain and prevent the long-term health complications linked to obesity, according to Prof Kenny.
He said the specialist clinics have 'already transformed the lives of thousands of children and young people – supporting them to lose weight, live heathier lives and improve their mental health'.
A 16-year-old schoolgirl, named only as Kirsty, described going to Sheffield Children's NHS Foundation Trust CEW clinic two years ago as 'the best decision I ever made', even though she was 'really nervous' at first about attending.
Kirsty was severely bullied about her weight and height at school, which led her to struggle with her mental health and gain more weight.
She said: 'Talking about my mental health helped me a lot. The team also taught me a lot about food groups, portion sizes and lots of other things.
'Now I am the best I have ever felt, I am the lowest weight I have ever been and still losing weight. I am getting a lot of help with my mental health and also still getting a lot of other support.'
CEW clinic patients can face a range of complex conditions and challenges, according to an analysis of thousands of patients' demographic and obesity-linked health data presented at the European Congress on Obesity in Malaga, Spain.
A high proportion have a neurodevelopmental disorder, including 24% who had autism or 23% with a learning disability.
Major health complications such as metabolic dysfunction-associated steatotic liver disease was recorded in 30% of patients, 21% had obstructive sleep apnoea and 21% also suffered from hypertension.
More than 40% of patients also lived within the most deprived neighbourhoods, according to the researchers from Leeds Beckett University, Sheffield Hallam University, Leeds University and the University of Bristol.
Young people could be referred to a CEW clinic if they have a body mass index (BMI) above the 99.6 percentile, which is considered severe obesity, especially in children and young people, and a complication because of their excess weight.
Specialist NHS doctors, nurses, psychologists, social workers and dietitians are at hand to assess their complications, provide tailored help with diet and lifestyle changes, and give mental health support and coaching.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
2 hours ago
- Time Business News
Left Waiting and Losing Hope – How One Patient Found Relief Through Releaf UK When the NHS Couldn't Help
Every weekday, almost 13,000 new mental-health referrals land on NHS desks across the United Kingdom—far more than stretched community teams can absorb. For the people behind those forms the delay is not abstract: it means panic attacks unchecked, sleep lost, jobs at risk and, in the worst cases, lives cut short. This article follows one such patient and examines why catching psychiatric illness early is not only humane but also a hard-nosed economic imperative. Britain's Growing Mental-Health Backlog NHS England processed a record 4.6 million mental-health referrals last year, with typical waits of 12 weeks for an assessment and, in some counties, up to 18 months for specialist talking therapies. The Royal College of Psychiatrists warns that one in three people referred for depression will spiral into crisis if left untreated for more than three months. Behind every statistic is a household coping with sleepless nights, cancelled plans and mounting uncertainty. The Cost of Delay: Survival Rates Under Pressure Timely care can be the difference between recovery and tragedy. A Lancet meta-analysis tracking 34,000 adults found that evidence-based treatment within six weeks of diagnosis cut suicide attempts by 45 percent over two years. For first-episode psychosis, the National Institute for Health and Care Excellence reports a 50 percent improvement in five-year survival when therapy begins within 14 days of referral. These findings highlight how crucial timeliness is to well-being in healthcare, as every extra week on the waiting list chips away at a patient's odds of staying alive. Productivity on the Line: Why Business Leaders Should Care Delays also drain the balance sheet. Deloitte's 2024 UK Mental-Health Report calculated that poor mental health cost employers £59 billion in absenteeism, presenteeism and staff turnover—nearly £1,800 per employee. Organisations that installed early intervention programmes, such as on-site counselling or rapid referral partnerships, saw an average 5:1 return on investment. In manufacturing alone, stress-related absences translate to 12.7 million lost working days each year—enough to halt the entire aerospace sector for four straight weeks. Emma's Story: Fourteen Months in Limbo Emma Hughes, a 29-year-old graphic designer from Leicester, illustrates the human toll. After a sudden bereavement she developed severe anxiety, intrusive thoughts and chronic insomnia. Her GP referred her for cognitive behavioural therapy (CBT), but the confirmation letter warned of a '40–60-week wait.' Deadlines slipped; sick notes piled up; her self-confidence collapsed. 'Each morning started with a panic attack,' she remembers. By month ten she had exhausted paid leave and faced redundancy. 'I felt invisible—like no one believed how bad it was.' Discovering an Alternate Route Searching for private options, Emma found Releaf's psychiatric care pathway ( a Care Quality Commission-registered clinic offering multidisciplinary assessments within days. Unlike many self-pay services that focus narrowly on prescriptions, Releaf pairs consultant psychiatrists with therapists, nutritionists and sleep specialists. Emma's team designed a stepped-care plan: CBT delivered over secure video, structured sleep-hygiene coaching and, when conventional anxiolytics caused intolerable side-effects, a physician-supervised trial of adjunctive cannabis therapy—a form of cannabinoid treatment tailored to her needs. Six weeks later her sleep stabilised at seven hours a night; by week twelve she had returned to 80 percent of her billable workload. Data on Early Intervention and Workplace Recovery Emma's rapid turnaround echoes wider research. The Centre for Mental Health shows that people receiving comprehensive care within two months of diagnosis are twice as likely to hold a full-time job a year later compared with those who wait more than six months. Replacement costs compound the burden: the Chartered Institute of Personnel and Development pegs the expense of replacing a professional-level employee at £30,600, excluding lost expertise. Early psychiatric care therefore functions as a productivity safeguard, not merely a welfare spend. The Emerging Role of Complementary Therapies Selective serotonin reuptake inhibitors (SSRIs) remain first-line for many disorders, yet growing evidence supports multimodal strategies that include exercise, nutrition and—in specialist settings—medical cannabis for mental health. NICE already endorses cannabinoid medicines for refractory epilepsy and chemotherapy-induced nausea, and pilot studies are exploring benefits for anxiety-related insomnia. For patients like Emma, whose genetics or side-effects rule out standard pharmacology, these adjuncts can mean the difference between chronic disability and daily function. What Swift Access Could Mean for the UK Economy If the NHS achieved its own 28-day referral-to-treatment goal for common mental disorders, economists at the Institute for Public Policy Research estimate a productivity gain of £7.4 billion annually—enough to fund 35,000 additional psychiatric nurses. Meeting that benchmark will require a mixed-economy model in which accredited private providers, including specialized facilities like an addiction treatment center, absorb overflow demand and employers view mental-health budgets as investments. Releaf's rapid-access pathway shows how nimble, multidisciplinary care can slot into that ecosystem, sparing patients the agony of delay and easing pressure on public services alike. TIME BUSINESS NEWS
Entrepreneur
2 hours ago
- Entrepreneur
Entrepreneur UK's London 100: DrDoctor
DrDoctor has become one of the most trusted healthtech partners to the NHS, transforming how millions of patients access and manage their care. Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur United Kingdom, an international franchise of Entrepreneur Media. Industry: Healthcare Tom Whicher, CEO and founder of DrDoctor, is driving the shift to hybrid healthcare across the NHS – blending technology with human care. Under Tom's leadership, DrDoctor has become one of the most trusted healthtech partners to the NHS, transforming how millions of patients access and manage their care. Founded in 2012, the company connects fragmented systems across hospitals, community services, and patients to power a hybrid model. Today, DrDoctor manages over 140m appointments for 36m patients and is trusted by more than 70 NHS organisations, covering 64% of the country. It has delivered £100m of value to the health system in the UK. In 2024, Tom launched DrDoctor's Smart Centre, powered by AI – a set of pioneering products that predict which patients are most at risk of missing appointments and dynamically optimises clinic capacity through targeted, automated interventions. Early results have shown that Smart Centre reduces missed appointments by 30%. The team has grown by 45% over the past year to 146 people, fuelled by a £10m investment round led by YFM Equity Partners. With 2023 revenues exceeding £10m and a current valuation of £80m, DrDoctor is delivering both commercial success and system-level change against a backdrop of NHS reform.
Yahoo
3 hours ago
- Yahoo
Weight-loss jabs could soon be among most commonly used NHS drugs, top doctor says
Weight-loss jabs could soon become among the most commonly used drugs, the NHS's top doctor has said. Professor Sir Stephen Powis said cheaper versions of the jabs, such as Mounjaro, could lead to widespread use and be as transformative as statins - one of the most highly prescribed drugs taken by around 7 million people in the UK. His comments come as the NHS prepares to roll out access to Mounjaro, also known as tirzepatide, in GP practices. Prof Powis told the NHS ConfedExpo conference the NHS needs to go 'further and faster' to 'turn the tide' on rising levels of obesity and said the drugs could one day be accessed in pharmacies. The outgoing medical director of NHS England told reporters the weight-loss jabs could also be targeted at patients waiting for operations who cannot have them due to their weight. But the government's chief medical officer, Professor Chris Whitty, warned the jabs would not be a 'get out of jail card' for public and social health measures. He told the conference: 'They're not a get out of jail card, which means we don't have to do other social things. It is unacceptable, for example, to be advertising obviously obesogenic foods to young children, on the basis of subsequently they might be able to have jabs to undo the damage which will otherwise be lifelong.' An estimated 1.5 million are taking weight loss jabs in the UK. The Independent recently reported on a case of a woman who was refused a hip operation due to her weight, who had been forced to pay privately for the jabs as she struggled to access them through the NHS. Later this month, GPs in England will be allowed to prescribe Mounjaro for the first time. Patients previously needed to access the drugs through a special weight loss service. Prof Powis hailed the rollout in GP surgeries as an 'exciting milestone' and said NHS officials are also examining ways to 'broaden access to the drugs', such as through pharmacies and digital services. Around 29 per cent of adults in the UK are obese. Prof Powis said: 'Right now, obesity is estimated to cost the NHS approximately £11.4 billion every year – this financial burden is unsustainable for the NHS and wider economy. 'We have to turn the tide. We have to and will go further, and faster. 'In just a few years from now, some of today's weight loss drugs will be available at much lower cost. This could completely transform access to these innovative treatments. He said eventually there would be more drugs coming onto the market, which means prices would likely fall. He said: 'We have been through this with statins, and the use of statins is now very different from when they first came out, and I've no doubt that will be the same for these drugs.' 'So I think over time it's highly likely that they will become more widespread, the evidence base will increase, we will learn better how to deploy them, we'll learn how long people need to be on them, and in terms of weight reduction, how much weight reduction is maintained once people come off – that's a big unknown,' he said. But he said he was not 'starry-eyed' about weight loss drugs, adding they are 'no silver bullet'. He told reporters: 'These medicines can be harmful if they are prescribed without the right checks and wraparound care – they can have side effects, including nausea, dehydration and inflammation of the pancreas, and a worrying number of people are continuing to access them without appropriate checks via the internet. Around 220,000 people are expected to benefit from the rollout of jabs at GP services over the next three years.
